The New York Times: Lower Drug Prices: New Proposals Carry Lots of Promises
Mark Merritt, chief executive of PCMA, dislikes the proposal and believes the Medicare coverage is a “sound program”
Mark Merritt, chief executive of PCMA, dislikes the proposal and believes the Medicare coverage is a “sound program”
“In effect, the era of high list prices and high rebates for insulin is over” In case you missed it, Alex Brill, founder and CEO of Matrix Global Advisors (MGA) and former policy director and chief economist for the House
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is announcing the additions of Jack Linehan as General Counsel, Agnita Kote as Chief Financial Officer, Zach Pleasant as Director, Technology and Operations, and the promotion of Amanda Frost to Vice
(Washington, D.C.) – As independent drugstore lobbyists descend on Albany for their special interest lobby day, the Pharmaceutical Care Management Association (PCMA) released the following statement: “Pharmacy benefit managers (PBMs) advocate on behalf of New York’s consumers and health plan sponsors by negotiating
JC Scott speaks with Doug Long, Vice President of Industry Relations at IQVIA, about the impact of COVID-19 on the pharmaceutical market. IQVIA is a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare
(Washington, D.C.) — As drugstore lobbyists descend on Albany today, it is important to highlight how pharmacy benefit managers (PBMs) advocate for consumers and health plan sponsors in the fight to keep prescription drugs accessible and affordable. It is equally
A proposal announced by President Trump last month was to send older Americans $200 discount cards to offset prescription costs. It’s not going to happen before the election, and maybe not ever.
It did not cut the prices of any blockbusters like the cancer treatment Keytruda or the diabetes drug Januvia.
Mark Merritt said the real problem was the high prices set by drugmakers. “Getting rid of rebates and other price concessions would leave patients and payers, including Medicaid and Medicare, at the mercy of drug manufacturers’ pricing strategies,” Mr. Merritt
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the eve of Governor Andrew Cuomo’s 2020 State of the State Address and the start of the state legislative session in Albany:
©2024 PCMA. All Rights Reserved.